Table 2.
Topical Tacrolimus in anterior segment disorders
| Disease | Reference/Authors | No. of eyes (patients) | Tacrolimus form | Frequency | Study design |
|---|---|---|---|---|---|
| CAU | 20/Taddio et al. | 6 (3) | Solution 0.1% | 3 times | Case series |
| Scleritis | 16/Miyazaki et al. | 2 (2) | Ointment 0.02% | 1–4 times | Retrospective |
| Scleritis | 31/Lee et al. | 4 (4) | Ointment 0.02% | 1–4 times | Retrospective |
| GVHD | 32/Jung et al. | 24 (13) | Ointment 0.02% | 1–2 times | Retrospective |
| GVHD | 33/Tam et al. | 2 (1) | Ointment 0.03% | 2 times | Case report |
| GVHD | 34/Ryu et al. | 14 (7) | Ointment 0.02% | 2 times | Prospective |
| GVHD | 35/Abud et al. | 48 (24) | Suspension 0.05% | 2 times | Prospective |
| OCP | 39/Hall et al. | 2 (1) | Ointment 0.03% | once daily | Case report |
| OCP | 40/Michel et al. | 2 (1) | Ointment 0.03% | once daily | Case report |
| OCP | 31/Lee et al. | 2 (1) | Ointment 0.02% | 1–3 times | Retrospective |
| SJS | 31/Lee et al. | 11 (5) | Ointment 0.02% | 1–3 times | Retrospective |
| SLK | 44/Kymionis et al. | 4 (2) | Ointment0.03% | 2 times | Case report |
| AK | 47/Ghanem et al. | 10 (7) | Suspension 0.03% | 2 times | Prospective |
| AK | 48/Levinger et al. | 11 (11) | Ointment 0.03% | 2 times | Prospective |
| Dry Eye | 50/Moscovici et al. | 48 (42) | Suspension 0.03% | 2 times | Prospective |
| PKC | 51/Kymionis et al. | 2 (2) | Ointment 0.03% | 2 times | Case report |
| PKP | 59/Dhaliwal et al. | 4 (4) | Ointment 0.03% | 2 times | Case series |
| PKP | 60/Magalhaes et al. | 36 n | Suspension 0.03% | 2 times | Retrospective |
| PKP | 61/Reinhard et al. | 20 20) | Solution 0.06% | 3 times | Prospective |
CAU = chronic anterior uveitis; GVHD = Graft Versus Host Disease; OCP = Ocular Cicatricial Pemphigoid; SJS = Stevens-Johnson syndrome; SLK = Superior limbic keratoconjunctivitis; AK = Adenoviral Keratitis; PKC = Phlyctenular keratoconjunctivitis; PKP = Penetrating keratoplasty